Breakthrough in COVID-19 Treatment: New Study on Oral Prodrug of Remdesivir Shows Promising Results

Strategic Insights -

Researchers at the University of North Carolina have made significant strides in the development of an oral prodrug of remdesivir, a medication used to treat COVID-19, which has shown promising results in in vitro and in vivo studies. The study, published in Science Translational Medicine, demonstrated the antiviral activity of the oral prodrug, GS-621763, against SARS-CoV-2 in multiple cell lines and human primary lung cell culture systems.

Key Takeaways:

  • The study demonstrated the in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug of GS-441524, the parent nucleoside of remdesivir.
  • GS-621763 exhibited antiviral activity against SARS-CoV-2 in lung cell lines and two different human primary lung cell culture systems.
  • The dose-proportional pharmacokinetic profile of GS-621763 translated to dose-dependent antiviral activity in mice infected with SARS-CoV-2.
  • Therapeutic administration of GS-621763 reduced viral load and lung pathology, and improved pulmonary function in a COVID-19 mouse model.
  • A direct comparison of GS-621763 with molnupiravir, an oral nucleoside analog antiviral, showed both drugs to be similarly efficacious in mice.

The research was funded by the Burroughs Wellcome Fund, the Hanna H. Gray Fellowship, the NIH National Institute of Allergy & Infectious Diseases (NIAID), the North Carolina Policy Collaboratory at UNC at Chapel Hill, and the North Carolina Coronavirus Relief Fund.

Statistics:

  • The study demonstrated the antiviral activity of GS-621763 against SARS-CoV-2 in multiple cell lines and human primary lung cell culture systems.
  • The dose-proportional pharmacokinetic profile of GS-621763 translated to dose-dependent antiviral activity in mice infected with SARS-CoV-2.
  • Therapeutic administration of GS-621763 reduced viral load and lung pathology by [percentage or amount not specified].
  • The study showed similar efficacy between GS-621763 and molnupiravir in mice.

Sources:

  • Science Translational Medicine, "Therapeutic Treatment With an Oral Prodrug of the Remdesivir Parental Nucleoside Is Protective Against Sars-cov-2 Pathogenesis In Mice."
  • University of North Carolina, Department of Epidemiology
  • Burroughs Wellcome Fund
  • Hanna H. Gray Fellowship from the Howard Hughes Medical Institute
  • NIH National Institute of Allergy & Infectious Diseases (NIAID)
  • North Carolina Policy Collaboratory at UNC at Chapel Hill
  • North Carolina Coronavirus Relief Fund